TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook

TD Cowen has reiterated a Buy rating on DexCom (NASDAQ:DXCM) stock, setting an $84.00 price target, aligning with InvestingPro’s Fair Value. The firm raised its estimates for 2026-2028, anticipating significant margin expansion, despite recent concerns about a slowdown in the U.S. continuous glucose monitoring market. DexCom recently surpassed Q4 2025 earnings and revenue expectations, and other analysts like Evercore ISI and Stifel also maintain optimistic ratings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments